1. Cardiogenic Shock Following Acute Myocardial Infarction: What's New?
- Author
-
O. Burattini, Alessandro Santo Bortone, Palma Luisa Nestola, Stefano Favale, Ottavio Di Cillo, Martino Pepe, Giuseppe Patti, Annagrazia Cecere, Nicola Signore, Cinzia Forleo, and Arturo Giordano
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Myocardial Infarction ,Shock, Cardiogenic ,Acute myocardial infarction ,030204 cardiovascular system & hematology ,Critical Care and Intensive Care Medicine ,Revascularization ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,multivessel revascularization ,medicine ,Humans ,Myocardial infarction ,IABP ,Intensive care medicine ,mechanical circulatory support ,business.industry ,Cardiogenic shock ,cardiogenic shock ,percutaneous coronary intervention ,Percutaneous coronary intervention ,030208 emergency & critical care medicine ,medicine.disease ,Shock (circulatory) ,Emergency Medicine ,Myocardial infarction complications ,Observational study ,medicine.symptom ,business - Abstract
Cardiogenic shock (CS) is a state of critical end-organ hypoperfusion primarily due to cardiac dysfunction. This condition is the most common cause of death in patients affected by acute myocardial infarction (AMI). Despite early revascularization, prompt optimal medical therapy, and up-to-date mechanical circulatory supports, mortality of patients with CS remains high.The objective of this review is to summarize epidemiology, pathophysiology, and treatment options of CS in light of the new European Society of Cardiology (ESC) recommendations. The latest European guidelines on myocardial revascularization have reviewed the previous guidelines with respect to early multivessel revascularization and routine use of intra-aortic balloon pump (IABP) in patients with AMI-related CS.Most of the current evidences come partly from randomized trials, but mostly from observational registries because of the difficulty to test different treatments in this life-threatening clinical setting.Some of the latest studies highlight the potential crucial benefit of newly introduced mechanical circulatory support devices, although evidences are not sufficient to definitely assess the benefit/risk ratio of the different systems.Many questions remain unanswered in this field, and further trials are advocated to better elucidate the best medical, reperfusion, and circulatory support approaches aimed to improve the poor prognosis of patients with CS after AMI.
- Published
- 2020